Filing Details

Accession Number:
0001209191-21-037475
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-06-02 21:43:35
Reporting Period:
2021-06-01
Accepted Time:
2021-06-02 21:43:35
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1557746 Aclaris Therapeutics Inc. ACRS Pharmaceutical Preparations (2834) 460571712
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1654450 Frank Ruffo C/O Aclaris Therapeutics, Inc.
640 Lee Road, Suite 200
Wayne PA 19087
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-06-01 33,189 $0.00 184,909 No 4 M Direct
Common Stock Disposition 2021-06-02 12,587 $21.51 172,322 No 4 S Direct
Common Stock Disposition 2021-06-02 2,450 $22.30 169,872 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2021-06-01 33,189 $0.00 33,189 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 M Direct
Footnotes
  1. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
  2. Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on June 1, 2021 pursuant to preexisting sell-to-cover elections.
  3. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.06 to $22.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.06 to $22.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. The shares underlying these restricted stock units vested in two equal annual installments beginning on June 1, 2020.